Tirzepatide
Dual GIP/GLP-1 receptor agonist. 5-dose escalation (2.5 → 15 mg) over 20+ weeks. Up to ~22% weight loss in SURMOUNT-1.
At a glance
- Common vial size
- 24 mg
- Reference dose
- 15 mg
- Frequency
- Once weekly
Reference titration protocol
2.5 → 5 → 7.5 → 10 mg, 4 weeks per tier, once weekly.
| Step | Dose | Duration | Administrations / week |
|---|---|---|---|
| 1 | 2.5 mg | 4 weeks | 1× |
| 2 | 5 mg | 4 weeks | 1× |
| 3 | 7.5 mg | 4 weeks | 1× |
| 4 | 10 mg | 4 weeks | 1× |
A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.
Open this configuration in the calculatorClinical notes
- Step up no faster than every 4 weeks
- Same MTC contraindication as semaglutide
Available formulations
Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.
- 60 mg · Injectable503A
- Injectable503A
- Oral Dissolving Tablet503A
- Solution503A
- Standard presentation503A
References
Often used with
Compounds commonly discussed alongside Tirzepatide in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.
- BPC-157503A503BRUO
Commonly paired for GI tolerability questions.
31 presentations carried - Ipamorelin503A503BRUO
Discussed for lean-mass preservation on incretin therapy.
6 presentations carried - NAD+503A503BRUO
Frequently requested alongside for energy support.
10 presentations carried - 5-Amino-1MQ503A503BRUO
Discussed as an oral metabolic adjunct.
6 presentations carried
Pricing and ordering are for verified accounts
VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.